Bleomycin-induced lung disease is characterized by fibroblast proliferation and pulmonary fibrosis. In these studies, we' demonstrate that fibroblasts are relatively resistant to clinically relevant amounts (below 10 U/ml) of bleomycin and that these levels of bleomycin augment fibroblast proliferation in response to various fibroblast growth factors. These observations suggest that one mechanism by which bleomycin causes pulmonary fibrosis is augmentation of fibroblast proliferation.
Introduction
Bleomycin, a chemotherapeutic agent useful in the treatment of testicular carcinoma, lymphoma, and squamous cell carcinomas, is known to produce lung parenchymal injury and interstitial fibrosis in man and in animal models (1-3). The development oflung disease is the major limiting side effect ofthis drug. Histologic studies of human lung (1) and various animal models (4-7) ofthe disease have demonstrated evidence ofinjury to a variety of lung cells, including a denuding of the vascular basement membrane. This injury is also associated with aggregation of platelets, evidence of fibroblast proliferation, and the development of fibrosis. The latter observation suggests that fibroblasts are relatively resistant to the cytotoxic effects of bleomycin. In these studies, we present data that not only suggest that fibroblasts are relatively resistant to bleomycin-induced injury compared with endothelial cells, but also that bleomycin at or below peak therapeutic serum levels augments fibroblast proliferation in response to known platelet-derived growth factors (8) (9) .
Methods
Cell cultures. Human umbilical vein endothelial cells were isolated from fresh umbilical cords after exposure to type I collagenase (I mg/ml for 8 min; Cooper Biomedical Co., Malvern, PA) as described by Johnson et al. (10) . The cells were washed and then resuspended in medium 199 (M-199 (12) . The release of LDH by isolated cells exposed to a range of bleomycin concentrations was also examined in the present study. In this study, the correlation between the release of LDH and [3H]uridine was highly significant (r = 0.886; P < 0.001).
Platelet New England Nuclear, Boston, MA) for 4 h at 370C. The tissue culture medium was then removed and the cells were washed with 5% cold trichloroacetic acid. After washing, 0.4 ml of 0.25 N sodium hydroxide was added to solubilize the cells; then 0.1 ml of I N hydrochloric acid was added to neutralize the NaOH. The liquid was then placed in a counting vial. 10 ml of scintillation fluid (Ready Solv HP; Beckman Instruments, Inc.) was also added to the vials before counting in a scintillation counter. Incorporation of [3H1thymidine was used as an index of cell proliferation. These radioassay techniques of cell proliferation were confirmed by actual cell counts.
Statistics. Analysis of all dose response data was accomplished using a one-way analysis of variance. Significant differences between groups were assessed by Student's t test.
Results
Bleomycin caused significant cell injury to both fibroblasts and endothelial cells in a dose-dependent manner (Fig. 1) . There was significantly greater cytotoxicity for endothelial cells than for fibroblasts (P < 0.05). At doses of bleomycin that are normally achieved in plasma (below l0-4 U/ml), no significant injury of fibroblasts could be detected.
As expected, PS (1:6 dilution) alone, PDGF (1 U/ml) alone, and FGF (100 ng/ml) alone caused a significant increase in fibroblast proliferation compared with control cultures (0.4% serum alone; Fig. 2 , a-c; each P < 0.05). The addition of bleomycin at doses of 10-8 U/ml resulted in a further significant increase in fibroblast proliferation above that caused by the growth factors alone (Fig. 2, a-c revealed that PS alone caused a significant increase in cell numbers from 13±2 X I04 cells/ml to 27±1 X 104 cells/ml ( Fig. 4 ; P < 0.05). Bleomycin alone caused no increase in fibroblast proliferation above 0.4% serum alone, but bleomycin plus PS resulted in significant increases in proliferation over medium alone (13±2 X 104 cells/ml vs. 36±2 X 104 cells/ml; P < 0.05) and PS alone (27±1 X 104 cells/ml vs. 36±2 X 104 cells/ml; P < 0.05).
To study the dose-response effects of bleomycin on fibroblast proliferation, various amounts of bleomycin were added to PSexposed fibroblasts (Fig. 5) . At very high doses (10-2_10-4 U/ml), bleomycin inhibited the fibroblast growth response to PS to a level that was significantly less than PS alone (P < 0.05). In fact, fibroblast growth in the presence of the highest dose of bleomycin (10-2 U/ml) plus PS was no different from that seen with 0.4% serum alone. As the amount of bleomycin decreased, there was an augmentation of the fibroblast growth response to PS with a maximal response at 10-8 U/ml of bleomycin (P < 0.05). Overall, there was a significant dose dependence of fibroblast proliferation in response to the combination of bleomycin and PS ( Fig. 5 ; P < 0.05).
Discussion
The present studies demonstrate that fibroblasts are less sensitive in vitro to bleomycin injury than endothelial cells and are only injured by relatively high doses of bleomycin. The observation that relatively high doses of bleomycin inhibit fibroblast proliferation is consistent with those ofAbsher et al. (16) , who showed that exposure of fibroblasts to bleomycin at doses of lO-' U/ml and above resulted in an inhibition of cell growth. Although the mechanism by which bleomycin injures cells was not evaluated in the present studies, prior studies have shown that bleomycin may cause cell injury by lipid peroxidation (17) (18) and by DNAstrand nicking (19) (20) DNA at adenosine-thymidine bonds (13), the results of the standard [3H]thymidine incorporation assay were also confirmed by actual cell counts. These studies revealed that increases in fibroblast proliferation seen with the combination of bleomycin and PS were actual increases in cell numbers. In fact, there was very close agreement in the percent increase in fibroblast proliferation as determined by [3H]thymidine incorporation (133±13% over PS alone) and by visual counts (136±5% over PS alone).
At this time, the findings of this study can only be directly related to established fibroblast lines and may not be representative of human lung fibroblasts in vivo. These observations may be relevant, however, to the pathogenesis of bleomycin-induced lung fibrosis. Prior histologic studies and data from animal models (4-6) have shown that bleomycin-induced lung disease may be divided into various stages. Initially, injury occurs to endothelial cells. This is followed by denuding of the vascular basement membrane and the formation of platelet aggregates and microthrombi. Finally, there is fibrosis of the tissue from collagen accumulation, which is associated with an increase in fibroblast numbers. The present studies strongly suggest that bleomycin may play a role in lung fibrosis not only by causing cell injury but also by augmenting fibroblast proliferation in response to growth factors to which these cells are exposed as a result of injury to the endothelium. These factors likely include growth factors derived from aggregated platelets as well as other factors that may be present in serum (8-9, 21, 22) .
A precise mechanism for the augmentation of growth factorinduced fibroblast proliferation by bleomycin is not clear. Bleomycin may stimulate the fibroblast to generate a factor that augments fibroblast proliferation. Such a factor by itself would not cause fibroblast proliferation but would instead augment the response to another growth factor. Another mechanism by which bleomycin might augment the response to a growth factor is by blocking the generation of a suppressive factor produced by the fibroblast itself. It is known, for example, that fibroblasts produce prostaglandin E2 (PGE2), which functions to suppress cell growth (23) . Although the effect of bleomycin on PGE2 release has not been studied in fibroblasts, Clark et rophages exposed to bleomycin secrete markedly decreased amounts of PGE2 (24) (25) . In their model system, this decrease of PGE2 production is associated with fibroblast proliferation and increased fibrosis. These observations and those ofthe present study suggest that bleomycin might cause fibroblast proliferation by inhibiting not only PGE2 production by fibroblasts but also PGE2 production by other cells in the environment of the fibroblast. The results of these studies can also be directly related to the doses of bleomycin used for chemotherapy. In this regard, pharmacologic studies of bleomycin given by intravenous infusion have determined that patients receiving 30 U/d attain a mean peak plasma level of2 X 10-4 U/ml (26). Initial elimination is rapid, but after 12 h the elimination rate changes to a beta half-life of 8.9 h (26). Regression analysis reveals an elimination rate constant (K) of 7.8 X 10-2 h-'. Using a standard elimination half-life equation, Cp = (Cpl) (e-K), where Cp is the plasma concentration at time ofinterest, Cp, is the plasma concentration at time 0 and t is the hours from time 0, it can be estimated that bleomycin would be present in plasma at levels > 10-9 U/ml for -126 h. These observations suggest that chemotherapeutic regimens that use bleomycin on a weekly basis will expose patients to levels ofbleomycin that augment fibroblast proliferation and injure endothelial cells for up to 5 d after each dose throughout the course of treatment. In patients with impaired renal function, bleomycin clearance would be prolonged four-to fivefold for a plasma concentration of > 10-9 U/ml for 500 h postinfusion. If the results of this study can be related to the in vivo effects of bleomycin, then patients are exposed to concentrations of the drug that cause injury to endothelial cells and possibly other lung cells for a prolonged period oftime. Fibroblasts, however, may not only be unharmed by these doses of bleomycin but may also be stimulated to increase their cell growth in response to various growth factors generated in the environment of the fibroblast in response to the injury of endothelial cells.
